Skip to main content

Table 3 Analysis of overall survival in IHCC patients

From: A new pathological classification of intrahepatic cholangiocarcinoma according to protein expression of SSTR2 and Bcl2

Univariate analysis

Multivariate analysis

Factors

n/n

5-year survival (%)

p value

Factors

Hazard ratio

95% C.I.

p value

Curability (A, B/C)

43/9

32.3/0.00

0.003

Curability (A, B/C)

1.634

0.566–4.306

0.348

T (1, 2/3, 4)

18/34

57.0/10.4

< 0.001

T (1, 2/3, 4)

2.847

0.944–9.313

0.064

N (0/1–3)

36/16

36.5/6.73

0.001

N (0/1–3)

3.091

1.348–7.002

0.008

cStage (I, II/III, IV)

15/37

61.9/13.0

< 0.001

    

Tumor type (MF/MF + PI)

20/32

38.6/19.2

0.163

    

Tumor location

(grossly peripheral/perihilar)

47/5

27.7/20.0

0.667

    

Differentiation (Cholangiolo/tub1/others)

6/14/32

40.0/17.9/30.8

0.235

    

SSTR2†, Bcl2‡ expression (p-Group H + U/p-Group P)

38/14

22.6/39.3

0.046

SSTR2, Bcl2 (p-Group H + U/p-Group P)

1.055

0.370–2.880

0.917

Tumor thrombus in the portal vein (−/+)

33/19

35.7/9.40

0.001

Tumor thrombus in the portal vein (−/+)

2.237

0.963–5.383

0.061

Tumor thrombus in the hepatic vein (−/+)

45/7

25.9/28.6

0.660

Intrahepatic metastasis (−/+)

2.049

0.712–5.474

0.176

Intrahepatic metastasis (−/+)

44/8

30.3/12.5

0.030

    

CA19-9§ (< 100/> 100)

24/27

48.3/6.00

0.008

CA19-9 (< 100/> 100)

1.485

0.591–3.793

0.400

CEA|| (< 5/> 5)

37/15

27.4/26.6

0.810

    

Surgical procedure (Partial resection/segmentectomy / lobectomy)

5/8/39

30.0/38.1/25.5

0.627

    

Lymphadenectomy (+/−)

29/23

17.1/40.4

0.1027

    
  1. † SSTR2 somatostatin receptor 2
  2. ‡ Bcl2 bcell leukemia/lymphoma 2
  3. § CA19-9 carbohydrate antigen 19-9
  4. || CEA carcinoembryonic antigen